Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be Sotyktu successor.